-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250

Benzinga·10/30/2026 16:57:21
Listen to the news
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.